A Phase 2 interventional study of ACT-128800 and Placebo in Plaque Psoriasis, sponsored by Actelion. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-11-13.
Sponsored by Actelion · Phase 2, Interventional, and Treatment
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 66 is close to the median of 70 across 1,447 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Actelion is the lead sponsor of 140 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 24 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: ACT-128800
Drug: Placebo
ACT-128800 administered orally once daily
Matching placebo capsules administered orally once daily
Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.
Time frame: Baseline to week 6
"Clear - almost clear" Physician Global Assessment (PGA) at Week 6 visit.
Time frame: Week 6
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Actelion